RNA-binding proteins use a dual binding mechanism involving zinc finger (ZnF) domains and intrinsically disordered regions ...

The San Diego, USA firm has simultaneously announced that the US Food and Drug Administration (FDA) has granted Orphan Drug ...

Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease CareHOUSTON, Aug. 25, ...

RNA-binding proteins use a dual binding mechanism involving zinc finger (ZnF) domains and intrinsically disordered regions ...

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Messenger RNA, or mRNA – a technology that can instruct cells to fight disease – has fueled breakthroughs from Covid vaccines ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

The quest for a vaccine against HIV has been going on for about 40 years — almost as long as the virus that causes AIDS has ...